News releases
20 of 53 items
Continuing Discussions 8 Dec 2009
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company, as announced on 3 November 2009.
Posting of Annual Report & Accounts 6 Nov 2009
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, confirms that its Annual Report and Accounts for the year ended 30 June 2009 is today being posted to shareholders.
Possible Offer 3 Nov 2009
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today announces that it is in discussions which may or may not lead to an offer being made for the Company. The Company further confirms that it is seeking a sale or merger of the Company in order that the value of its pipeline can be maximised. Piper Jaffray Ltd. has been appointed to advise the Company in connection with this process.
Preliminary results for the year ended 30 June 2009 30 Sep 2009
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, is pleased to announce its preliminary results for the year ended 30 June 2009
Notice of Preliminary Results 1 Sep 2009
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on neurodevelopmental disorders, will announce its preliminary results for the year ended 30 June 2009 on Wednesday 30 September 2009.
Shareholder Update 28 May 2009
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on neurodevelopmental disorders, today announces an interim update to its shareholders on significant progress during the past three months.
Share Price Movement 26 Mar 2009
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on developmental disorders, notes the existence of market rumour and the recent movement in its share price. The Company confirms that it received an indicative indication of interest with respect to a possible M&A transaction from a third party and that this interest is not being pursued. It further confirms that it is not currently in M&A discussions and is not aware of any specific reason for the share price movement.
Half-year results for the six months ended 31 December 2008 17 Mar 2009
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on developmental disorders, is pleased to announce its half-year results for the six months ended 31 December 2008.
Autism Speaks reports Neuropharm's SOFIA results 18 Feb 2009
NEW YORK, NY (2/18/2009) - Autism Speaks today announced initial results reported for the first industry-sponsored trial of the Autism Clinical Trials Network (ACTN), the Study of Fluoxetine in Autism (SOFIA). These results showed that fluoxetine was not effective for reducing repetitive behaviors in children and adolescents with Autistic Disorder as compared to placebo (non-medicinal sugar pill). The study was carried out in collaboration with study sponsor, Neuropharm Group Plc., a specialty pharmaceutical company focused on neurodevelopmental disorders.
Phase III results in SOFIA study of NPL-2008 18 Feb 2009
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, announces that the Phase III SOFIA study of NPL-2008 in Autistic Disorder did not achieve its primary endpoint. NPL-2008, a novel formulation of fluoxetine, was generally well tolerated by patients and no serious adverse events were reported.
20 of 53 items